HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Phase of Trial: Phase III
Latest Information Update: 02 Dec 2019
Price : $35 *
At a glance
- Drugs Vutrisiran (Primary)
- Indications Transthyretin-related hereditary amyloidosis
- Focus Therapeutic Use
- Acronyms HELIOS-B
- Sponsors Alnylam Pharmaceuticals
- 27 Nov 2019 Status changed from not yet recruiting to recruiting.
- 22 Nov 2019 According to an Alnylam Pharmaceuticals media release, the company expects to continue enrollment throughout 2020.
- 04 Nov 2019 Status changed from planning to not yet recruiting.